TMD.TO Titan Medical (TSX) at C$1.13 pre-market on 117,220 vol: check catalysts 16 Mar 2026

TMD.TO stock is trading at C$1.13 in the pre-market on heavy activity after an open at C$0.05 and a previous close of C$0.05. Volume hit 117,220 shares versus an average volume of 45,936, making this a clear high-volume mover on the TSX in Canada. The intraday range is C$0.05–C$1.13, and market cap stands at C$128,295,000. We use Meyka AI’s real-time signals to connect the volume spike to liquidity, valuation and short-term catalysts for traders and longer-term investors.

Pre-market price and volume action for TMD.TO stock

Titan Medical Inc. (TMD.TO) shows a sharp pre-market gap to C$1.13 on 117,220 shares, a 2.55x relative volume versus the 50-day average. This move follows an open at C$0.05 and a prior close at C$0.05, implying intraday volatility and a trading range from C$0.05 to C$1.13. Traders should note the average volume 45,936 figure when sizing positions.

News, catalysts and what could be driving TMD.TO stock moves

No formal press release is in the public filing here, but the surge fits patterns of fresh retail interest, low float trading and possible corporate updates. Titan Medical is developing the Enos robotic single-access surgical system, which remains the main commercial catalyst for the Medical – Devices sector in Canada. Watch official filings and the company website for announcements before assuming momentum is sustained Titan Medical website.

Fundamentals and valuation snapshot for TMD.TO stock

Titan Medical reports a market cap of C$128,295,000 and 114,040,000 shares outstanding. Trailing EPS published in quotes is -1.73, with a reported PE listed as -0.65 on the quote feed, reflecting loss-based metrics. Price averages are 50-day C$0.07 and 200-day C$0.07, which highlights the recent spike versus historical trading. Key ratios show a current ratio of 2.78 and cash per share at C$0.07, supporting short-term liquidity.

Meyka AI grade, technicals and TMD.TO stock forecast

Meyka AI rates TMD.TO with a score out of 100: 68.68 / 100 — Grade B — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month target of C$1.75, implying +55.56% from the current C$1.125 reference price. Forecasts are model‑based projections and not guarantees.

Risks, volatility and sector context for TMD.TO stock

Titan sits in the Healthcare Medical – Devices industry, a sector with mixed 3‑month performance and cautious investor sentiment in Canada. Key risks include continued operating losses, regulatory hurdles for the Enos system, and low float-driven price swings. With intraday price extremes between C$0.05 and C$1.13, expect high volatility and rapid bid-ask spreads that can amplify gains or losses.

High-volume trading strategies and watchlist items for TMD.TO

For traders, use tight risk controls, size positions to withstand large moves, and monitor level II liquidity. For longer-term investors, wait for confirmatory filings, device regulatory milestones, or meaningful revenue guidance. Track catalysts, average volume shifts, and filings on the TSX and Titan Medical site. For a quick reference, see our Meyka stock page for TMD.TO for live updates Meyka: TMD.TO stock page.

Final Thoughts

TMD.TO stock is a classic high-volume mover on the TSX this pre-market session, trading at C$1.13 on 117,220 shares versus an average of 45,936, which signals outsized short-term liquidity. Fundamentals show a mixed picture: trailing EPS of -1.73 and cash per share near C$0.07, but a current ratio of 2.78 that supports short-term operations. Meyka AI rates the stock 68.68 / 100 (B, HOLD) and models a 12‑month target of C$1.75, an implied +55.56% from the C$1.125 reference. Forecasts are model-based projections and not guarantees. Short-term traders should prioritise liquidity and confirmed catalysts. Long-term investors should wait for clinical, regulatory or commercial milestones for the Enos system before increasing exposure. For official company information see Titan Medical’s site and our live Meyka feed for updates Titan Medical website Meyka: TMD.TO stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.